Close
CDMO Safety Testing 2026
Novotech

New technique to speed up drug development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

QIAGEN and NVIDIA Join Forces to Advance AI-Driven Drug Discovery

QIAGEN's Digital Insights bioinformatics division is set to integrate...

Bioprocess Analytics Improving Biologics Manufacturing

The immense complexity of modern biopharmaceutical production is being navigated through the strategic and systematic application of bioprocess analytics improving biologics manufacturing. By leveraging real-time data streams and advanced monitoring tools, manufacturers can gain a granular, molecular-level understanding of cellular behavior and the surrounding environmental conditions within the bioreactor. This proactive, data-driven approach allows for immediate, automated adjustments that optimize therapeutic yield, ensure absolute product consistency, and significantly streamline the arduous path toward commercial-scale production in a highly regulated global environment.

Cell Therapy Quality Control Improving Clinical Outcomes

The long-term success of advanced medicinal products is fundamentally dependent on a rigorous and comprehensive approach to cell therapy quality control improving clinical outcomes. By implementing stringent, multi-stage testing for identity, purity, potency, and safety, manufacturers can guarantee that every individual dose delivered to a patient meets the highest possible standards of GMP compliance. This systematic and data-driven oversight minimizes clinical risks and enhances the reproducibility of complex treatments, ultimately leading to more predictable and successful therapeutic results in the rapidly evolving field of regenerative medicine.
- Advertisement -

Scientists working at the European Molecular Biology Laboratory in Grenoble, France have developed a new technique that enables them to introduce up to 15 fluorescent markers to a mammalian cell in one go. They say their findings could help speed up drug development and screening.

The study was funded in part by the P-CUBE (‘Protein production platforms’) project, which has clinched EUR 6.6 million through the Research Infrastructures budget line of the EU’s Seventh Framework Programme (FP7).

EMBL’s Imre Berger previously developed a technique that allowed scientists to create the equivalent of a make-up brush that is applied only once and highlights different features simultaneously. So cells could be given fluorescent labels to mark various cellular components in different colours, for example blue for the nucleus, yellow for the tubulin (a component of the cell’s scaffolding), red for the mitochondria, cyan for the membranes of vesicles called endosomes, and purple for the other membrane structures. This technology was created by Dr Berger as part of a method called MultiBac and used for expressing protein complexes in insect cells.

In this latest study, published in the journal Nature Communications, Dr Berger and Philipp Berger from the Paul Scherrer Institut (PSI) in Villigen, Switzerland joined forces to take this technology a step further, adopting the concept to mammalian cells like our own for the first time. This essentially involved rapidly engineering a single vector to deliver a theoretically unlimited number of foreign genes, to a cell.

To date, the scientists have successfully delivered up to 15 genes in this way. The protein encoded by each of those genes can carry a fluorescent label, so this makes multiple labelling much more efficient than previous methods. The new labelling technique for mammalian cells, called MultiLabel, could help make drug development and screening considerably faster, since it allows scientists to precisely label many cellular components involved in a given disease process and follow them all at the same time.

‘The introduction of heterologous genetic information, particularly of multiple genes, into mammalian cells is a key technology in contemporary experimental biological research,’ the researchers said.

‘The co-expression of fluorescently tagged sensors is required to simultaneously analyse multiple parameters in living cells and the co-expression of several proteins is necessary to manipulate cell fate in stem cell biology. Current technologies for multigene expression in mammalian cells are inefficient, inflexible and time-consuming.’

The team explained that MultiLabel is ‘a novel and highly efficient modular plasmid-based eukaryotic expression system’.

The P-CUBE project aims to provide greater, free access for European users to the most advanced techniques in cloning, expression, protein characterisation and crystallisation. To this end, the British and Swiss-based scientists involved in the project regularly share expertise to improve technologies and standardise procedures, with the ultimate aim of disseminating this expertise throughout Europe.

ย 

World Pharma Today brings together the global pharmaceutical industry โ€” from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives โ€” through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

QIAGEN and NVIDIA Join Forces to Advance AI-Driven Drug Discovery

QIAGEN's Digital Insights bioinformatics division is set to integrate...

Bioprocess Analytics Improving Biologics Manufacturing

The immense complexity of modern biopharmaceutical production is being navigated through the strategic and systematic application of bioprocess analytics improving biologics manufacturing. By leveraging real-time data streams and advanced monitoring tools, manufacturers can gain a granular, molecular-level understanding of cellular behavior and the surrounding environmental conditions within the bioreactor. This proactive, data-driven approach allows for immediate, automated adjustments that optimize therapeutic yield, ensure absolute product consistency, and significantly streamline the arduous path toward commercial-scale production in a highly regulated global environment.

Cell Therapy Quality Control Improving Clinical Outcomes

The long-term success of advanced medicinal products is fundamentally dependent on a rigorous and comprehensive approach to cell therapy quality control improving clinical outcomes. By implementing stringent, multi-stage testing for identity, purity, potency, and safety, manufacturers can guarantee that every individual dose delivered to a patient meets the highest possible standards of GMP compliance. This systematic and data-driven oversight minimizes clinical risks and enhances the reproducibility of complex treatments, ultimately leading to more predictable and successful therapeutic results in the rapidly evolving field of regenerative medicine.

GMP Cytokines Advancing Cell Therapy Manufacturing

The rapid transition of cell-based treatments from the experimental laboratory stage to the standard of clinical care is being enabled by the availability of GMP cytokines advancing cell therapy manufacturing. These vital signaling molecules are absolutely essential for the successful expansion, specific differentiation, and functional activation of therapeutic cell populations, such as CAR T cells used in oncology. By strictly adhering to Good Manufacturing Practice standards, suppliers ensure that these critical raw materials possess the high purity, consistent potency, and clinical safety required for human applications, thereby reducing product variability and significantly enhancing the success rate of regenerative medicine.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป